



August, 2009

Marketing Approval for Glaumox™ (acetazolamide sodium) 500mg Powder for Injection

Phebra is very pleased to announce that it has achieved marketing approval for Glaumox™ in Australia.

Glaumox™ is indicated for the adjunctive treatment of: oedema due to congestive heart failure; drug-induced oedema; centrencephalic epilepsies (petit mal, unlocalised seizures); chronic simple (open-angle) glaucoma; secondary glaucoma; and preoperatively in acute angle-closure glaucoma, where delay of surgery is desired in order to lower intraocular pressure.

“Glaumox™ is an important therapeutic option and an essential injectable drug for Australian hospitals”, said Dr Mal Eutick, CEO of Phebra, “we have been making Glaumox™ available to the Australian market as an unapproved medicine under the Therapeutic Goods Regulations Schedule 5A, for some time and are very pleased to have achieved marketing approval in Australia, which will streamline its availability”.

Phebra will be marketing Glaumox™ to Australian hospitals and supply is now available.

Phebra is an Australian hospital speciality pharmaceutical company.

At Phebra, we create critical medicines that save and improve lives.

Glaumox is a trademark of Phebra Pty Ltd